Overview

Zanubrutinib + Venetoclax in CLL/SLL

Status:
Not yet recruiting

Trial end date:
2028-10-28

Target enrollment:

Participant gender:

Summary

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: - zanubrutinib (BGB-3111) - venetoclax

Phase:

Phase 2

Details

Lead Sponsor:

Jennifer R. Brown, MD, PhD

Collaborator:

BeiGene

Treatments:

Venetoclax
Zanubrutinib